Abstract:Objective:To evaluate the effectiveness of gonadotropin-releasing hormone agonist (GnRH-a) combined with recombined-human chorionic gonadotropin (r-hCG) trigger (dual trigger) in improving the low proportion of mature oocytes in ovarian normal responders in GnRH antagonist cycles.Methods:Retrospective study was preformed to compare the stimulation characteristics of 366 in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles between March 2016 and August 2017 in Reproductive Medical Science Center of Obstetrics & Gynecology Department, Peking University Third Hospital. Patients were divided into group A (normal ovarian responders who were triggered with r-hCG only during IVF treatment resulted in low proportion of mature oocytes and failure IVF attempt, n=123), group B (dual trigger group, n=123), and group C (different patients of the corresponding period form group B, triggered with r-hCG only, n=120). The general characteristics and treatment outcomes were compared among these three groups. Results:The basic characteristic date including age, assisted reproductive technology (ART) indications, duration of infertility, basal hormonal level among the three groups were not statistically significant ( P>0.05). The ICSI fertilization rate (90.4% vs. 83.8%， P<0.001), and the rate of metaphase-II (M II) oocyte in group B was significantly higher than that in group A (77.6% vs. 44.7%， P<0.001). In addition, patients in group B had a significantly higher number of high-quality embryos (1.6±0.6 vs. 0.3±0.3， P=0.01)， the number of embryos transferred (1.8±0.8 vs. 0.6±0.4， P=0.02), the clinical pregnancy rate (35.5% vs. 0%, P<0.001) and the live birth rate （31.8% vs. 0%， P<0.001） in the fresh embryo transfer cycle， the clinical pregnancy rate (32.1% vs. 0%, P<0.001) and the live birth rate （28.0% vs. 0%， P<0.001） in the frozen-thawed embryo transfer cycle while lower rate of cycle cancellation (10.6% vs. 27.6%， P<0.001) than group A. As compared with group C, the number of oocytes retrieved was not statistically significant, while the number of high-quality embryos (1.6±0.6 vs. 4.0±2.6， P=0.02), the number of two pronucleus (2PN) embryos (5.0±2.8 vs. 6.3±3.8， P=0.03) and the clinical pregnancy rate (35.5% vs. 58.0%， P<0.001) and the live birth rate （31.8% vs. 46.8%， P=0.02） in the fresh embryo transfer cycle， the clinical pregnancy rate (32.1% vs. 51.3%, P=0.01) and the live birth rate （28.0% vs. 44.4%， P=0.03） in the frozen-thawed embryo transfer cycle were significantly lower. Conclusion:For patients who have normal ovarian response but low proportion of mature oocytes, co-administration of GnRH-a and standard-dose r-hCG (dual trigger) for final oocyte maturation can improve their IVF outcome.

Intrauterine injection of human chorionic gonadotropin improves the pregnancy rates in in-vitro fertilization-embryo transfer cycles of repeated failures

[Frozen-Thawed Embryo Transfer (FET) Versus Fresh Embryo Transfer in Clinical Pregnancy Rate During in Vitro Fertilization-Embryo Transfer].

[Analysis of Low-Quality Embryo Transfer Strategy in in Vitro Fertilization and Embryo Transfer Cycle].

The Number of Previous Failed Embryo Transfer Cycles is an Independent Factor Affecting Implantation Rate in Women Undergoing IVF/ICSI Treatment A Retrospective Cohort Study

Comparison of Progesterone Measurement on Day Of, and Day After, HCG Administration in IVF–embryo Transfer Cycles

Correlative factors on multiple gestation and pregnancy in in vitro fertilization and embryo transfer

Intrauterine administration of peripheral blood mononuclear cells activated by human chorionic gonadotropin in patients with repeated implantation failure: A meta-analysis

Intramuscular injection of human chorionic gonadotropin as luteal phase support in artificial cycle frozen-thawed embryo transfer does not improve clinical outcomes: a parallel, open-label randomized trial

Gonadotropin Releasing Hormone Agonist and Standard Dosage of Human Chorionic Gonadotropin Trigger Improve the in Vitro Fertilization and Embryo Transfer/intracytoplasmic Sperm Injection Treatment Prognosis of Patients with History of Poor Fertilization Outcomes

Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection in Patients With “Unpredictable” Poor Response to Gonadotropin-Releasing Hormone Antagonist Protocol

Clinical Outcome of Intrauterine Administration of Peripheral Mononuclear Cells or Human Chorionic Gonadotropin in Unexplained Implantation Failure.

Effect of Luteal- Phase Gonadotropin- Releasing Hormone Agonist Administration on Clinical Pregnancy Rate after Intracytoplasmic Sperm Injection

Clinical Analysis of 12 491 Cycles Treated in Embryo Transfer Program

Effects of Different Fertilizations Upon Serum HCG Level of IVF Versus ET in Early Pregnancy

Co-administration of gonadotropin-releasing hormone agonist and recombined-human chorionic gonadotropin in patients with low proportion of mature oocytes during in vitro fertilization treatment

A repeated gonadotropin-releasing hormone agonist trigger improves pregnancy outcomes of frozen-thawed embryo transfer in GnRH antagonist cycles: a retrospective propensity-matched score analysis

The Value of HCG Serum Concentrations after Trigger in Predicting Pregnancy and Live Birth Rates in IVF–ICSI

Live births from in vitro fertilization-embryo transfer following the administration of gonadotropin-releasing hormone agonist without gonadotropins: Two case reports

Abdominal Ultrasound-Guided Embryo Transfer Improves Clinical Pregnancy Rates After In Vitro Fertilization: Experiences from 330 Clinical Investigations

The Clinical Pregnancy Outcome of Artificial Insemination by Donor (AID) and in Vitro Fertilization with Donor Semen (IVF-D) Treatment

Effect of controlled transferred embryo numbers on reducing in vitro fertilization embryo transfer multiple pregnancy rate in Beijing